Emerging Tumor Marker Diagnostic Testing Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers, 2019

Emerging Tumor Marker Diagnostic Testing Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers, 2019

  • July 2019 •
  • 185 pages •
  • Report ID: 5796008 •
  • Format: PDF
Emerging Tumor Marker Diagnostic Testing Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers, 2019

This 185-page report provides detailed assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.

The report also presents strategic assessments of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in RandD, collaborative arrangements and business strategies.

Contains 185 pages


Companies Profiled
Company Assessments

- Abbott
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Clinical Genomics
- Decode Genetics
- DiaSorin
- Diazyme
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic
- Janssen Diagnostics
- Kyowa Medex
- Leica Biosystems
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- PerkinElmer
- Polymedco
- Qiagen
- Quest Diagnostics
- Roche
- Scienion
- Sequenom
- Siemens Healthineers
- Takara Bio
- Theradiag
- Thermo Fisher
- Tosoh
- Vermillion
- Wako Pure Chemicals